Peijian Peng
Sun Yat-sen University(CN)Fifth Affiliated Hospital of Sun Yat-sen University(CN)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Head and Neck Cancer Studies, Cancer Immunotherapy and Biomarkers, HER2/EGFR in Cancer Research
Most-Cited Works
- → Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial(2016)520 cited
- → KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma(2017)288 cited
- → The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs(2015)243 cited
- → Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study(2021)99 cited
- → Low Prognostic Nutritional Index (PNI) Predicts Unfavorable Distant Metastasis-Free Survival in Nasopharyngeal Carcinoma: A Propensity Score-Matched Analysis(2016)72 cited
- → Development and External Validation of Nomograms for Predicting Survival in Nasopharyngeal Carcinoma Patients after Definitive Radiotherapy(2015)61 cited
- → Perineural Invasion and TAMs in Pancreatic Ductal Adenocarcinomas: Review of the Original Pathology Reports Using Immunohistochemical Enhancement and Relationships with Clinicopathological Features(2014)57 cited
- → EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47(2024)43 cited
- → Multicenter phase II study of capecitabine combined with nedaplatin for recurrent and metastatic nasopharyngeal carcinoma patients after failure of cisplatin-based chemotherapy(2013)34 cited
- → Association between PD-L1 Expression on Tumour-Infiltrating Lymphocytes and Overall Survival in Patients with Gastric Cancer(2017)34 cited